Maravai LifeSciences Holdings, Inc. Class A Common Stock

Day range

$7.32 – $7.60

Open

$7.32

Prev close

$7.32

Volume

1.27M

Market cap

$1.09B

Shares out

148.99M

P/E

—

P/S

5.22

P/B

5.33

P/FCF

—

ROE

-37.8%

ROA

-12.8%

Debt/Equity

0.86

Div yield

0.00%

As of Oct 23, 2026

• Debt retirementJun 3, 2026

  Proceeds from the New Term Loan, together with approximately $98.5 million cash on hand, were used to prepay in full outstanding borrowings under, and to terminate, the prior Credit Agreement, dated as of October 19, 2020 (the "Prior Credit Agreement"), among the Borrower, Cygnus Technologies, LLC, TriLink Biotechnologies, LLC, Topco and Morgan Stanley Senior Funding, Inc.

• Annual meeting resultsMay 29, 2026

  On May 26, 2026, Maravai LifeSciences Holdings, Inc. held its 2026 Annual Meeting of Shareholders. The Company's shareholders elected the following nominees for director to serve for three-year terms expiring at the Company's 2029 Annual Meeting of Shareholders: Bernd Brust, Gregory T. Lucier, and Luke Marker.

• Director departureOct 27, 2025

  Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD each agreed to voluntarily resign from the Board effective as of the close of business on such date (the 'Effective Date'). None of the resignations were related to any disagreement with the Company's management, the Board or any committee of the Board on any matter related to the Company's operations, policies or practices.

• Executive officer departureAug 11, 2025

  On August 7, 2025, the Company's Board of Directors eliminated the positions held by Rebecca Buzzeo, Executive Vice President and Chief Commercial Officer of the Company, and Pete Leddy, Ph.D., Executive Vice President and Chief Administrative Officer of the Company. As a result, Ms. Buzzeo's last day of employment with the Company is expected to be September 2, 2025, and Dr. Leddy's last day of employment with the Company is expected to be October 2, 2025.

• Auditor dismissalJul 18, 2025

  On July 16, 2025, the Audit Committee approved the dismissal of Ernst & Young LLP ('EY') as the Company's independent registered public accounting firm.

Days to cover

5.9

Short interest

13.83M

Avg volume

2.34M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 22, 2025
• MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 14, 2025
• MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 8, 2025
• MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
  negativeGlobeNewswire Inc.· May 5, 2025
• MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
  negativeBenzinga· May 5, 2025